Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?
NCT ID NCT07733115
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether adding an experimental immune therapy (QL1706) to standard chemotherapy can shrink tumors in people with advanced biliary tract cancer that has a specific marker (PD-L1 positive). About 38 participants will receive the combination every three weeks for up to eight cycles, then continue QL1706 alone. The study measures tumor response, how long benefits last, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two immune checkpoint inhibitors (PD-1 and CTLA-4 antibodies) called QL1706, plus standard chemotherapy drugs gemcitabine and cisplatin
- What this could lead to
- If effective, this combination could offer a new first-line treatment option for people with advanced biliary tract cancer whose tumors have a specific marker (PD-L1 positive).
- What could go wrong
- This is a small, early-phase trial with only 38 participants and no comparison group, so results may not apply broadly. Immune-related side effects from QL1706 can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- New hope for bile duct cancer: drug duo targets tough tumors
- Radiation plus immunotherapy shows promise in bile duct cancer trial